Introduction
The E2F family of transcription factors are central regulators of cell cycle progression (Trimarchi and Lees, 2002; Attwooll et al., 2004; Bell and Ryan, 2004) . In cycling cells, the activating E2Fs (E2F-1, E2F-2 and E2F-3) form complexes with members of the DP family of proteins enabling association with a consensus DNAbinding site (Bandara et al., 1993; Helin et al., 1993) . Accordingly, this results in transactivation of a number of genes directly involved in DNA replication and cell division including cdc25a, cyclin E and dihydrofolate reductase Vigo et al., 1999) .
In normal cells, the activity of E2F proteins is subject to regulation by the retinoblastoma susceptibility protein, (pRb), and its related proteins p107 and p130 (Trimarchi and Lees, 2002) . During quiescence, 'activating' E2F/DP complexes (those containing a DP protein and either E2F-1, -2 or -3) are bound to DNA in a ternary complex with pRb, blocking the ability of E2F to engage the basic transcriptional machinery. Additionally, active repression occurs through the ability of pRb to recruit histone deacetylases and methyltransferases that modify histones and switch off transcription (Magnaghi-Jaulin et al., 1998; Nielsen et al., 2001; Vandel et al., 2001) . Following mitogenic stimulation, phosphorylation of pRb by cyclin-dependent kinase (cdk) complexes results in dissociation of pRb from E2F, permitting target gene activation and subsequent cell cycle progression . If E2F activity is not constrained via normal regulatory pathways, it has potent oncogenic potential and, in fact, E2F is deregulated in the majority of human tumours. Although rarely mutated itself, E2Fs deregulation can occur through loss or mutation of pRb or hyperphosphorylation of pRb through amplification of cyclins or loss of cdk inhibitors such as p16 (Sherr and McCormick, 2002) .
The 'activating' E2Fs, and primarily E2F-1, have also been implicated in the induction of programmed cell death both in vitro and in vivo (Qin et al., 1994; Shan and Lee, 1994; Wu and Levine, 1994; Kowalik et al., 1995; Field et al., 1996; Pan et al., 1998; Vigo et al., 1999; La Thangue, 2003; Bell and Ryan, 2004; Denchi and Helin, 2005) . Crucially, apoptosis as a result of pRb deletion in mice can be rescued by the generation of double knockout mice, which also lack either E2F-1 or E2F-3 (Tsai et al., 1998; Ziebold et al., 2001) . Moreover, the observation that E2F-1 À/À mice spontaneously develop tumours in a number of tissues indicates that, in addition to its oncogenic potential, E2F-1 has a tumour suppressive role in vivo (Yamasaki et al., 1996) . Understanding this apoptotic function of E2F and how it may be disrupted during tumour development is therefore critical.
In vitro and in vivo experiments have shown that E2F-1-driven apoptosis can be dependent or independent of the p53 tumour suppressor protein (Macleod et al., 1996) . The ability of E2F-1 to induce apoptosis in a p53-dependent manner is mediated partially through transactivation of the gene encoding p14ARF (the Alternate Reading Frame of the INK4a locus; p19ARF in mice) (Quelle et al., 1995; Bates et al., 1998) . Normally, p53 levels are maintained via a negative feedback loop with Mdm2, which targets p53 for ubiquitin-mediated degradation (Haupt et al., 1997; Kubbutat et al., 1997) . p14ARF inhibits this effect causing stabilization of p53 and, in some situations, results in programmed cell death (Pomerantz et al., 1998; Stott et al., 1998; Zhang et al., 1998; Honda and Yasuda, 1999) . E2F-1 has also been shown to induce apoptosis in a p53-dependant manner in mice and cells that are lacking p14ARF (Russell et al., 2002; Tolbert et al., 2002; Tsai et al., 2002; Rogoff et al., 2004) . For example, E2F-1 can transactivate several DNA damage responsive kinases, such as ATM and Chk2, which phosphorylate p53 and alleviate its Mdm2-mediated degradation (Rogoff et al., 2002 (Rogoff et al., , 2004 Berkovich and Ginsberg, 2003) . Furthermore, E2F-1 can transactivate factors that promote p53-mediated activation of apoptotic target genes (Chen et al., 2005; Fogal et al., 2005; Hershko et al., 2005) .
E2F-1 can also induce apoptosis independently of p53. It is able to directly transactivate the p53 family member p73, which shares many of p53's target genes and can induce programmed cell death Lissy et al., 2000; Stiewe and Putzer, 2000) . In addition, E2F-1 has also been shown to directly transactivate components of the apoptotic machinery such as apoptosis protein activating factor (Apaf-1), and caspase 7 (Moroni et al., 2001; Furukawa et al., 2002; Nahle et al., 2002) .
These proapoptotic E2F target genes, however, do not account for E2F's complete apoptotic response. A number of reports have indicated that mutants of E2F-1, which lack the transactivation domain, are still able to induce death (Hsieh et al., 1997; Phillips et al., 1997; Liu and Greene, 2001) . As these mutants retain the ability to bind DNA, they may act by displacing endogenous repressive E2F complexes and causing gene expression through alleviation of repression, or 'de-repression'. It has also been shown that these mutants can bind to DNA and cause repression at other promoters. The prosurvival Bcl2 family member, Mcl1, has been shown to be repressed by E2F-1 in this way (Croxton et al., 2002) . However, the extent to which these mechanisms are responsible for transactivation-deficient cell death and the full cell death response from E2F-1 is yet to be determined.
We describe here refinement of a transactivationdeficient mutant of E2F-1. We show that a region of only 75 amino acids containing the DNA-binding region is sufficient to induce death in a p53-independent manner, and that this activity is also present in E2F-2 and -3. However, owing to the lack of a DP dimerization domain this mutant is no longer able to bind DNA. This region is therefore unable to activate, repress or derepress gene expression and defines a novel mechanism of E2F-driven programmed cell death.
Results
Induction of transformation, but not apoptosis requires transactivation from E2F-1 In order to investigate the transforming and death inducing function of E2F-1, we generated expression constructs for two previously described mutants Helin and Harlow, 1994) . E2F-1-D374 is a C-terminal truncation of E2F-1 that lacks the entire transactivation and pRb-binding domains but retains the DNA-binding domain. E2F-1-132E has a glutamic acid substitution at amino-acid 132 within the DNAbinding domain that abrogates DNA binding ( Figure 1a) . To test the transactivation potential of these mutants against two apoptotic target genes of E2F-1, luciferase reporter assays were performed with reporter constructs containing promoter elements from Apaf-1 and p73. In agreement with previous reports, Apaf-1 and p73 were effectively transactivated by wildtype E2F-1 Stiewe and Putzer, 2000; Moroni et al., 2001; Brooks et al., 2002) (Figure 1b) . However, no activation of Apaf-1 or p73 was seen following transfection of the DNA-binding mutant E2F-1-132E. This is consistent with studies using a reporter construct containing three tandem E2F-1-responsive elements (Hsieh et al., 1997; Phillips et al., 1997) . Analysis of E2F-1-D374 revealed that, although compromised in transactivation potential relative to wild-type E2F-1, it was able to induce the reporter by a small amount compared to the completely inert E2F-1-132E (approximately sixfold for p73 and threefold for Apaf-1, Figure 1b ). This likely indicates that these reporters are subject to negative regulation by endogenous repressive E2F complexes and that this repression is alleviated by E2F-1-D374 which displaces these complexes, effecting activation by de-repression.
These mutants of E2F-1 were next assessed for their ability to contribute to cellular transformation. Each of the E2F-1 mutants was retrovirally infected into NIH-3T3 cells. The cells were then assayed for their ability to form colonies in semi-solid agar. Wild-type E2F-1, but not E2F-1-D374 or E2F-1-132E, was able to induce the formation of colonies in this assay ( Figure 1c ). This underscores the importance of both DNA-binding and transactivation to the oncogenic potential of E2F-1.
Many tumours lack p53 functions however, the mechanisms by which E2F-1 induces apoptosis in the absence of p53 are not completely understood. To investigate this p53-independent cell death function of E2F-1 further, each of the E2F-1 mutants was transiently transfected into p53-null human osteosarcoma Saos-2 cells. The transfected population was then analysed by flow cytometry with the percentage of cells with a sub-G1 DNA content being taken as a measure of the apoptotic rate. After 48 h, 24% of the transfected population had a sub-G1 DNA content when wild-type E2F-1 was overexpressed ( Figure 1d ). This was increased to about 40% in cells where E2F-1-D374 was overexpressed. The higher amount of apoptosis brought about by overexpression of E2F-1-D374 has been previously observed and is probably due to the reduced negative regulation imposed on the protein by the lack of pocket protein binding (Phillips et al., 1997) . E2F-1-132E was unable to induce cell death, with the amount of apoptosis observed following transfection of this mutant being comparable to vector control ( Figure 1d ). This indicates that, in contrast to E2F-1-mediated transformation, the ability of E2F-1 to induce apoptosis is not dependent on transactivation.
An apoptotic activity of E2F-1 maps to the DNA-binding domain In order to investigate E2F-1's apoptotic potential further we decided to refine the region of E2F-1 necessary to induce apoptosis. A series of N-and Cterminal truncations were made ( Figure 2a ). In order to achieve equivalent expression and for easy detection, each of these constructs was fused at the C-terminus to the green fluorescent protein (GFP).
Analysis of these mutants for cell death potential by flow cytometry revealed that the fusion protein equivalent to E2F-1-D374 (T1) caused 23% of the transfected cells to have a sub-G1 DNA content after 48 h (Figure 2b) . Most of the other truncations gave comparable levels of apoptosis. However, T6, T9 and T10 exhibited a relative inability to induce apoptosis despite equivalent expression to other apoptotic truncations as shown by Western blot analysis (Figure 2b and c).
The region which is uniquely lacking in T6, T9 and T10, but present in all apoptotic truncations, is the 75 amino acid DNA binding-domain comprising amino acids 117-191 of E2F-1. To determine if this domain was sufficient for the induction of apoptosis, a GFP fusion involving this domain was constructed (described hereafter as T11) (Figure 2a ). Transient transfection into Saos-2 cells revealed that T11 gave comparable levels of apoptosis to the original transactivation-deficient mutant, E2F-D374 (T1) (Figure 2d ). T9 (amino acids 245-374) or the GFP control induced little apoptosis despite being expressed at comparable levels to T11 (Figure 2e ).
The DNA-binding domains from E2F-2 and E2F-3 are able to induce programmed cell death There is a high degree of conservation in the DNAbinding domains of E2F-1, -2 and -3 ( Figure 3a) . As E2F-2 and -3 have also been shown to induce apoptosis (Vigo et al., 1999) , we next sought to determine whether the DNA-binding domains from these E2Fs could also induce programmed cell death. As can be seen in Figure 3b , expression of the DNA-binding domains from E2F-1, -2 and -3 all had the capacity to induce cell death. The amount of cell death seen from the DNAbinding domain of E2F-2 (E2F-2 DBD) was comparable to that seen for T11. Less death was seen from the DNA-binding of E2F-3 (E2F3 DBD), although this truncation was routinely expressed at slightly lower levels preventing exact quantitative evaluation of the E2F-3 cell death response relative to E2F-1 and -2 (Figure 3c ).
Induction of apoptosis by E2F-1 does not require DNA binding In order to effectively bind DNA, E2F needs to be bound in a heterodimer with a DP family member. Interaction occurs through the dimerization domain that comprises the adjacent leucine zipper and marked box regions of the protein ( Figure 1a ). As this domain is absent from the constructs T11, E2F-2 DBD and E2F-3 DBD, it is unlikely that they are able to efficiently bind either DP or DNA. However, it is conceivable that they may bind DNA as homodimers and induce cell death by de-repression of endogenous E2F complexes. We therefore analysed, in the context of E2F-1, the DNAbinding capacity of T11 by electrophoretic mobility shift assay.
Saos-2 cells were transiently transfected with DP1 together with either: E2F-1-WT, E2F-1-D374, E2F-1-132E or T11. After 24 h, nuclear extracts were incubated with an oligonucleotide containing a consensus DNAbinding site for E2F-1. Electrophoresis revealed that E2F-1-WT and E2F-1-D374 are able to form specific E2F-1-containing DNA complexes, verified by cold oligo competitions and antibody supershifts (Figure 4a and b). No DNA-binding complexes were evident in cells transfected with E2F-1-132E or T11 despite comparable expression of the mutants (Figure 4a and c). Similar DNA-binding complexes were seen following transfection of E2F-1-WT and E2F-1-D374 without transfection of DP1 (data not shown) indicating that E2F-1-WT and E2F-1-D374 can form DNA-binding complexes with endogenous DP under the conditions in which the apoptosis assays were conducted (Figures 1d,  2b and d) .
Initially, it seems contradictory that E2F-1 has an apoptotic activity that does not involve DNA binding as the E2F-1 mutant 132E (which does not bind DNA) cannot induce death. To investigate this, we generated a mutant of T11 containing the same mutation at amino acid 132E (T11 132E). This mutant, which was expressed at similar levels to T11, was, however, still able to induce death confirming that DNA binding is unnecessary for the apoptotic function of T11 ( Figure  4d and e). It also argues that, as well as inhibiting DNA binding, the 132E mutation changes the conformation of wild-type E2F-1 such that it also prevents the death inducing activity which would otherwise be seen from the T11 domain. As T11 is a domain of E2F-1 examined in isolation this suggests that this masking may require other regions of E2F-1, hence the introduction of 132E on T11 does not inhibit its effect.
Apoptosis from the E2F-1 DNA-binding domain does not involve transcriptional repression or 'de-repression' Although DNA-binding assays revealed no detectable DNA-binding activity of T11, it remained possible that T11, whether weakly bound to DNA as a homodimer or via an 'off-DNA' effect, could still exert a de-repression effect on promoters as has been reported for E2F-1-D374 (Hsieh et al., 1997; Phillips et al., 1997) . To test this, we analysed the effects of T11 on p73-Luc that we previously found to be de-repressed by E2F-1-D374 (Figure 1b) . In contrast to the effects of E2F-1-D374, but consistent with its inability to bind DNA, T11 was unable to effect any activation of p73-Luc giving luciferase values equivalent to E2F-1-132E (Figure 5a ). In addition, as a mutant of E2F-1 similar to E2F-1-D374 has also previously been shown to be able to repress the Mcl1 promoter (Croxton et al., 2002) , we also tested if T11 could effect repression of Mcl1. In agreement with the study from the Cress group (Croxton et al., 2002) , E2F-1 and E2F-1-D374 were able to repress the Mcl1 promoter indicating that this is an effect that does not require the E2F-1 transactivation domain (Figure 5b ). In contrast, E2F-1-132E and T11 do not repress the reporter. This has been previously observed for E2F-1-132E, which causes increased levels of reporter activity compared to cells transfected with vector alone (Croxton et al., 2002 and Figure 5b) . These results therefore confirm that T11 is not inducing apoptosis via a DNAbinding-dependent mechanism and indicates that in addition to transactivation, repression and de-repression, E2F-1 can induce cell death by mechanism(s) that do not involve gene regulation.
Discussion
E2F is frequently deregulated in human cancer, but has conflicting roles in tumour development. Further investigation of E2F's role in cell death regulation and cell cycle control, and how E2F integrates with other factors to determine cell fate is vital to our understanding and treatment of cancer. Although it is well established that the ability of E2F to promote cell cycle progression (and thereby contribute to transformation) requires transactivation of target genes, the ability to induce cell death is more complex and can be mediated by transactivation, repression and de-repression (Liu et al., 1998; Liu and Greene, 2001; Croxton et al., 2002; Bracken et al., 2004) . The data presented here add another layer of complexity by indicating that E2F can induce apoptosis by a novel mechanism that does not involve DNA binding, as indicated by the apoptotic capacity of T11, E2F-2 DBD and E2F-3 DBD.
Other studies have also investigated the involvement of specific domains from E2F and DP1 in the regulation of cell death. Domain swap experiments between E2F-1 and E2F-3 implicated the marked box from E2F-1 as being essential for the ability of E2F-1 to induce p53 and p73. As a result, E2F-1 constructs lacking this domain showed a considerable reduction in the ability to induce death (Hallstrom and Nevins, 2003) . In our study, in the absence of p53, the presence of the marked box was not essential for induction of death. Moreover, the DNAbinding domains from E2F-1, -2 and -3 were all able to cause death indicating that in our cell systems, the induction of cell death was not an E2F1-specific effect. The possibility remains, however, as has been suggested (Denchi and Helin, 2005) that the induction of death from E2F-2 and -3 is actually driven through E2F-1. Transfection of the DNA-binding domains from E2F-2 and -3 into cells where the endogenous E2F-1 had been reduced by RNAi would certainly be an interesting future experiment to resolve this issue.
In another report, analysis was made of the deathinducing activity of small peptides from DP1 (Bandara et al., 1997) . One peptide that induced death has a homologous region in E2F-1 that is contained within T11. It was shown that this DP1-derived peptide functions as a dominant-negative to endogenous E2F complexes, presumably by causing de-repression in a similar manner to E2F-1-D374. This was not the case for T11 (Figure 4d ) indicating that the homologous sequence in E2F-1 is not functionally equivalent to the peptide from DP1. Indeed, critical residues for the function of the DP peptide are not conserved in E2F-1 (Bandara et al., 1997) .
So what then is the mechanism of action of T11? As E2F-1 has been shown to homodimerise, it remained possible that T11 may bind to endogenous E2F-1 and affect its function. When this was tested, however, no binding was seen between T11 and E2F-1 (data not shown). It seems mostly likely though that T11 functions through a protein-protein interaction. Moreover, as we found that T11 and wild-type E2F-1 are located partially within the cytoplasm, it need not necessarily be the case that this protein-protein interaction occurs in the nucleus. One exciting possibility would be, as has been shown for p53 (Moll et al., 2005) , that E2F-1 may directly act to induce apoptosis at mitochondria. However, our analysis of the cytoplasmic distribution of T11 and wild-type E2F-1 did not show any co-localization at mitochondria making this possibility unlikely (data not shown). The mechanism of action of T11 therefore remains unknown, but is undoubtedly worthy of further investigation.
Ultimately, this study provides an exciting new angle to the control of cell death by E2F and cell death regulation in general. The elucidation of the mechanism of action of T11 will not only shed light on our understanding of E2F, but could also provide novel targets for therapeutic intervention. In particular, since T11 does not require p53 to induce death, the targeting of T11 interacting proteins for therapy design could potentially result in agents able to induce tumour cell death, regardless of the p53 status of the tumour.
Materials and methods
Cell culture, transfections and infections Saos-2 human osteosarcoma cells and NIH-3T3 cells were grown at 371C in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Calcium phosphate precipitation was used to transiently transfect cells. Sixteen hours after transfection, cells were washed and re-fed with fresh medium. Cells were then harvested at the times indicated in each assay. Retroviral infections were carried out as previously described . Briefly, cells were infected with either: pLPC vector alone, wild-type pLPC E2F-1, pLPC E2F-1-D374 and pLPC E2F-1-132E. After a 24-h recovery period in standard growth medium, cells were selected for 4 days in 2.25 mg/ml puromycin (Sigma, Poole, UK).
Plasmids
The plasmids pLPC-E2F-1, pLPC-E2F-1-D374 and pLPC-E2F-1-132E were generated by polymerase chain reaction (PCR) from wild-type E2F-1 as previously described Helin and Harlow, 1994) . Amplified sequences were cloned into the BamH1 of the CMV-driven retroviral expression vector, pLPC (a gift from Scott Lowe). Further 0 . The DNA-binding domains from E2F-2 and E2F-3 were amplified with the following primer pairs: E2F-2 (forward) ATAAAGCTTCGCACCATGAAAACCCCCAA ATCCCCCGGGGAG, (reverse) ATAGGATCCGGTACC CACTGGATGTTGTTCTTGGC; E2F-3 (forward) ATAA AGCTTCGCACCATGAAAACTCCAAAATCTCCCTCAG AA, (reverse) ATAGGATCCGGCATCCATTGGACGTTG TTTTTAGA. Amplified fragments were cloned into EGFP-N1 (BD Biosciences Clontech, Cowley, UK) and subsequently cut with NotI, blunted and cut with HindIII. pLPC was cut with BamHI, blunted then cut with HindIII and the fragments ligated. The reporter constructs were kindly provided by Kristian Helin (Apaf1-Luc), Doug Cress (Mcl1-Luc) and Tim Crook (p73-Luc) and have been previously described (Ding et al., 1999; Moroni et al., 2001; Croxton et al., 2002) .
Western blotting
Protein gel electrophoresis and Western blotting was conducted as previously described (Ryan and Vousden, 1998) . Membranes were probed with anti-GFP monoclonal antibody (Sigma), anti-p38 antibody (Cell Signalling, NEB, Hitchin, UK), or anti-actin antibody (A-4700, Sigma), using standard immunoblotting techniques.
Anchorage-independent growth assays Bacterial culture dishes were coated with 0.5% Noble Agar containing standard growth medium as described above. Cell suspensions of NIH-3T3 containing 2 Â 10 5 cells were mixed with an equal volume of top agar containing 0.6% Noble agar and double concentration growth medium, then layered on top of the base agar plates described above. Dishes were cultured for 2 weeks at 371C then visualized by microscopy for the appearance of colonies.
Cell death assays
After the treatments and times indicated, total populations of cells, including floating and adherent cells, were processed for flow cytometric analysis (FACScan, Becton Dickinson, Cowley, UK) as described previously (Ryan and Vousden, 1998) . Cells that had been transiently transfected, were co-transfected with pCMV-CD20 (kindly provided by Ed Harlow, Harvard Medical School), stained with a fluoresceince isthiocynate (FITC)-conjugated CD20 antibody (Becton Dickinson) and propidium iodide (Sigma) and sorted for fluorescence isothiocyanate fluorescence and DNA content. Cells transfected with EGFP-N1 vectors were sorted for GFP fluorescence and analysed for DNA content as above. The percentage of cells with a sub-G1 DNA content was taken as a measure of the apoptotic rate of the cell population.
Reporter assays
Saos-2 cells were transiently transfected with 5 mg of each reporter plasmid, 5 mg of pJ3Obgal and 0.5 mg of each E2F-1 construct as indicated. After 24 h , populations of adherent and non-adherent cells were lysed in luciferase lysis buffer (Promega, Southampton, UK) according to the manufacturer's instructions. Samples were assayed for luciferase activity and values obtained were normalized for transfection efficiency following assay for b-gal activity.
Electrophoretic mobility shift assays
Approximately 10 6 cells per sample were used for isolation of nuclear protein as previously described (Andrews and Faller, 1991) . Binding reactions to the following labelled oligonucleotides was carried out as reported (Ryan and Birnie, 1997) : E2A promoter sequences À71 to À50: 5 0 -GATCTAGTTTTC GCGCTTAAATTTGA-3 0 , 5 0 -GATCTCAAATTTAAGCGC GAAAACTA-3 0 , mutant E2A promoter sequence: 5 0 -GATC TAGTTTTCGATATTAAATTTGA-3 0 , 5 0 -GATCTCAAATT TAATATCGAAAACTA-3 0 . Antibodies used for supershift reactions were: E2F-1 specific (KH20/KH95, Upstate), nonspecific (p38 #9212, Cell Signalling Technology, NEB, Hitchin, UK).
